From: Treatment of COVID-19-associated ARDS with mesenchymal stromal cells: a multicenter randomized double-blind trial
UC-MSCs (n = 21)
Placebo (n = 24)
Number of doses received over 7Â days
2.7 (0.6)
2.7 (0.5)
 One
2 (9.5%)
1 (4.2%)
 Two
4 (16.7%)
 Three
17 (81%)
19 (79.2%)
Corticosteroids administered for 7Â days
15 (71.4%)